4-(3-4-dibutoxybenzyl)-2-imidazolidinone and trequinsin

Rolipram [(R,S)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone] has been shown to inhibit selectively the cAMP phosphodiesterase (PDE) of vascular smooth muscle. In order to further explore the structural requirements for selective PDE inhibition, we synthesized a series of rolipram derivatives differently substituted either at the pyrrolidinone or at the aromatic ring. Among these compounds, rolipram was the most active compound. Semirigid analogues were prepared and used for an evaluation of the active conformation of rolipram. Structural comparison with two other potent and chemically different smooth muscle cAMP-PDE inhibitors, trequinsin and Ro 20-1724, allows us to propose a first topological model of the smooth muscle cAMP-PDE pharmacophore.

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Chemical Phenomena; Chemistry; Cyclic GMP; Hydrolysis; Imidazoles; In Vitro Techniques; Isoquinolines; Molecular Conformation; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Pyrrolidinones; Rolipram; Tetrahydroisoquinolines